Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/d41586-019-03474-8 | DOI Listing |
Laryngoscope
December 2024
ENT Department, Misericordia Hospital, Grosseto, Italy.
Objective: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a challenging condition often managed with biologic therapies. This study compares the clinical effects and response times of dupilumab, omalizumab, and mepolizumab in Italian patients with severe uncontrolled CRSwNP.
Methods: This bicentric, retrospective study included 33 patients treated at two Italian hospitals between April and December 2023.
Alzheimers Dement
November 2024
Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Introduction: Heterozygous mutations in the progranulin gene (GRN) leading to decreased progranulin levels are one of the most frequent causes of inherited frontotemporal dementia (FTD). We evaluated progranulin levels in dried blood spots from capillary finger-stick collection (DBS).
Methods: Paired venous Ethylenediaminetetraacetic acid (EDTA) plasma and DBS samples were collected from each participant with or without pathogenic GRN mutations.
Cureus
October 2024
Medicine, Kalinga Institute of Medical Sciences, Bhubaneswar, IND.
J Vasc Surg Venous Lymphat Disord
November 2024
The Vascular Care Group (TVCG), Darien, CT; Vascular Anomalies and Malformations Program (VAMP), Yale School of Medicine, New Haven, CT; Division of Vascular Surgery, Department of Surgery, Yale New Haven Health, New Haven, CT. Electronic address:
Background: Although direct stick embolization (DSE) of low-flow vascular malformations (LFVMs) with off-label embolotherapeutic compounds is the current mainstay of therapy, systemic oral mammalian target of rapamycin (mTOR) inhibition has evolved into an important adjunctive therapy that is associated with frequent blood draws, systemic toxicity, and rebound signs and symptoms upon cessation. We herein report our experience with in-human DSE of LFVMs with an mTOR inhibitor for direct, intralesional targeting of the culprit mutated pathway without repeated systemic exposure.
Methods: Since 2020, 33 procedures involving DSE were performed in 25 patients with LFVMs using a patented formulation and technique involving the intravenously compatible mTOR inhibitor Yale-OCR7737, used as a liquid compound in a collagen matrix emulsion for added viscosity and intralesional residence.
PLoS One
November 2024
Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!